Parabilis Medicines (PBLS) Revenue & Revenue Breakdown
Parabilis Medicines Revenue Highlights
0
Latest Revenue (Q)
$2.11M
Parabilis Medicines Revenue by Period
Parabilis Medicines Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2025-12-31 | - | 100.00% |
| 2024-12-31 | - | - |
Parabilis Medicines generated - in revenue during NA 2025, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Parabilis Medicines Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2026-09-30 | $2.11M | 1328.38% |
| 2026-06-30 | $148.00K | 100.00% |
| 2026-03-31 | - | 100.00% |
| 2025-06-30 | - | 100.00% |
| 2025-03-31 | - | - |
Parabilis Medicines generated $2.11M in revenue during Q3 2026, up 1328.38% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Parabilis Medicines Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| MGNX | MacroGenics | $149.50M | $18.67M |
| GLUE | Monte Rosa Therapeutics | $123.67M | $54.37M |
| CTMX | CytomX Therapeutics | $76.20M | $1.69M |
| TNGX | Tango Therapeutics | $62.38M | - |
| FHTX | Foghorn Therapeutics | $30.91M | $83.54M |
| RLAY | Relay Therapeutics | $15.36M | - |
| IMNM | Immunome | $6.94M | - |
| CGEM | Cullinan Therapeutics | - | - |
| PBLS | Parabilis Medicines | - | $2.11M |
| CBIO | Crescent Biopharma | - | - |
| ZYME | Zymeworks | $-27.11M | $256.46M |